<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04273607</url>
  </required_header>
  <id_info>
    <org_study_id>19-5692.0</org_study_id>
    <nct_id>NCT04273607</nct_id>
  </id_info>
  <brief_title>Anticoagulation-free VV ECMO for Acute Respiratory Failure</brief_title>
  <acronym>A-FREE ECMO</acronym>
  <official_title>Anticoagulation-free VV ECMO for Acute Respiratory Failure: A Pilot Safety and Feasibility Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damian Ratano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Physicians' Services Incorporated (PSI) Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently international experts recommend therapeutic anticoagulation for veno-venous&#xD;
      extracorporeal membrane oxygenation (VV-ECMO). Reports and case series suggest that the&#xD;
      absence of therapeutic anticoagulation is safe for VV-ECMO. No randomized control trials have&#xD;
      assessed this. The aim of this pilot study is to assess safety and feasibility of an&#xD;
      &quot;anticoagulation-free strategy&quot; for veno-venous ECMO (VV-ECMO) in Acute respiratory distress&#xD;
      syndrome (ARDS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although anticoagulation targets and monitoring strategies vary around the world, the current&#xD;
      practice is still to anticoagulate patients on ECMO, mostly with UFH. However, the use of&#xD;
      heparin coated circuits has changed their thrombogenicity. Preliminary data suggest that a&#xD;
      low-dose unfractionated heparin (UFH) strategy is non-inferior to a therapeutic dose UFH.&#xD;
      Indeed, in daily practice, when a patient on ECMO has severe bleeding complications, UFH is&#xD;
      often stopped until the hemorrhagic issue is under control, sometimes for days. This has led&#xD;
      some to hypothesize that anticoagulation might not be necessary for VV-ECMO, and a few case&#xD;
      series report little to no increase in adverse events as a result. There are currently no&#xD;
      randomized controlled trials comparing anticoagulation to no anticoagulation for patients&#xD;
      supported with ECMO. Anticoagulation is, for physiological reasons, less necessary during&#xD;
      VV-ECMO than VA-ECMO and this is the reason why our pilot study will focus on VV-ECMO only.&#xD;
      Whereas the whole ECMO device is identical for both configurations, the risk of systemic&#xD;
      embolization (e.g., stroke) and its severe complications is much higher in VA-ECMO where&#xD;
      blood is reinjected directly into the systemic arterial system. Moreover, in the presence of&#xD;
      severely decreased left ventricular function requiring VA-ECMO, the risk of left ventricular&#xD;
      thrombus is very high and requires anticoagulation. During VV-ECMO, the risk of systemic&#xD;
      embolization is low because the whole circuit is on the right side of the heart and&#xD;
      relatively preserved biventricular function is needed to perform VV-ECMO&#xD;
&#xD;
      The hypothesis is that VV-ECMO is safe and feasible without therapeutic anticoagulation for&#xD;
      adults with ARDS.&#xD;
&#xD;
      The objectives of this study is to assess, through a pilot study, the safety and feasibility&#xD;
      of an &quot;anticoagulation free strategy&quot; for veno-venous ECMO (VV-ECMO) in acute respiratory&#xD;
      failure&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 6, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ECMO associated thrombotic complications</measure>
    <time_frame>through ECMO completion, an average of 14 days</time_frame>
    <description>Composite outcome of:&#xD;
ECMO membrane oxygenator function assessed by trans-membrane pressure drop (&gt; 10mmHg/l/min) and a membrane PaO2/FiO2 ratio (&lt; 200mmHg)&#xD;
Need to change ECMO circuit due to clotting or dysfunction&#xD;
Platelets drop &gt;50% in 24 hours and &lt;50 /mm3&#xD;
Development of a clinically significant thromboembolic event&#xD;
Clinical deep vein thrombosis, clinically suspected and confirmed by ultrasound&#xD;
Acute ischemic stroke, clinically suspected and confirmed by head-CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic complications</measure>
    <time_frame>through ECMO completion, an average of 14 days</time_frame>
    <description>Hemorrhagic complications assessed and adapted as per Bleeding Academic Research Consortium (BARC)&#xD;
Type 0: No bleeding&#xD;
Type 1: Bleeding requiring transfusion of packed red blood cells (PRBC) or reduction of UFH&#xD;
Type 2: Bleeding requiring transfusion of PRBC and reduction of UFH&#xD;
Type 3: Life-threatening bleeding requiring, transfusion of PRBC, surgical intervention or discontinuation of ECMO&#xD;
Type 4: Any fatal bleeding</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Increase in d-dimer levels</measure>
    <time_frame>through ECMO completion, an average of 14 days</time_frame>
    <description>D-dimers level (&gt;5000ng/ml or &gt;50% increase in 24 h)&#xD;
Need for transfusion of blood and blood-derived products related or not to a bleeding event&#xD;
Coagulation parameters during the ECMO period&#xD;
Amount of clot and fibrin visualized in the pre- and post-membrane side of the oxygenator daily (visual assessment) and after ECMO removal (assessed by a photographic quantification method).</description>
  </other_outcome>
  <other_outcome>
    <measure>Transfusion of blood and blood-derived products related or not to a bleeding event</measure>
    <time_frame>through ECMO completion, an average of 14 days</time_frame>
    <description>Amount of blood products transfused to patients in each groups during the course of ECMO</description>
  </other_outcome>
  <other_outcome>
    <measure>Coagulation parameters on ECMO</measure>
    <time_frame>through ECMO completion, an average of 14 days</time_frame>
    <description>Evaluation of fibrinogen (g/l), activated partial thromboplastin time (aPTT, seconds), prothrombin time (PT, seconds), thromboelastogram (if available), activated clotting time (ACT, seconds; if available)</description>
  </other_outcome>
  <other_outcome>
    <measure>Amount of clot and fibrin visualized in the pre- and post-membrane side</measure>
    <time_frame>through ECMO completion, an average of 14 days</time_frame>
    <description>Pragmatic quantification of clot visualized on both sides of the oxygenator by direct evaluation and by a photographic quantification method</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Extracorporeal Membrane Oxygenation Complication</condition>
  <arm_group>
    <arm_group_label>No anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will not receive unfractionated heparin during the course of ECMO. They will receive standard venous thromboembolism prophylaxis with subcutaneous enoxaparin or unfractionated heparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anticoagulation, ECMO standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in this arm will receive the standard of care anticoagulation with unfractionated heparin during the course of ECMO.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous Heparin</intervention_name>
    <description>The intervention group will receive prophylactic heparin instead of standard of care therapeutic intravenous heparin</description>
    <arm_group_label>No anticoagulation</arm_group_label>
    <other_name>Enoxaparin or unfractionated heparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient with ARDS on VV-ECMO&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to anticoagulation with UFH (known heparin-induced thrombocytopenia,&#xD;
             active hemorrhage, any surgery precluding the use of anticoagulation),&#xD;
&#xD;
          -  Indication for therapeutic anticoagulation (pulmonary embolism or deep vein&#xD;
             thrombosis, chronic anticoagulation therapy before ECMO insertion)&#xD;
&#xD;
          -  Low-flow (&lt;2 liters/min) VV-ECMO (ECCO2R)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damian Ratano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eddy Fan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Damian Ratano, MD</last_name>
    <phone>+1 416-340-3601</phone>
    <email>damian.ratano@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eddy Fan, MD, PhD</last_name>
    <phone>+1 416-340-3601</phone>
    <email>eddy.fan@uhn.ca</email>
  </overall_contact_backup>
  <reference>
    <citation>Krueger K, Schmutz A, Zieger B, Kalbhenn J. Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients. Artif Organs. 2017 Feb;41(2):186-192. doi: 10.1111/aor.12737. Epub 2016 Jun 3.</citation>
    <PMID>27256966</PMID>
  </reference>
  <reference>
    <citation>Whittlesey GC, Drucker DE, Salley SO, Smith HG, Kundu SK, Palder SB, Klein MD. ECMO without heparin: laboratory and clinical experience. J Pediatr Surg. 1991 Mar;26(3):320-4; discussion 324-5.</citation>
    <PMID>2030479</PMID>
  </reference>
  <reference>
    <citation>Wen PH, Chan WH, Chen YC, Chen YL, Chan CP, Lin PY. Non-heparinized ECMO serves a rescue method in a multitrauma patient combining pulmonary contusion and nonoperative internal bleeding: a case report and literature review. World J Emerg Surg. 2015 Mar 12;10:15. doi: 10.1186/s13017-015-0006-9. eCollection 2015.</citation>
    <PMID>25774211</PMID>
  </reference>
  <reference>
    <citation>Dornia C, Philipp A, Bauer S, Stroszczynski C, Schreyer AG, M端ller T, Koehl GE, Lehle K. D-dimers Are a Predictor of Clot Volume Inside Membrane Oxygenators During Extracorporeal Membrane Oxygenation. Artif Organs. 2015 Sep;39(9):782-7. doi: 10.1111/aor.12460. Epub 2015 Apr 7.</citation>
    <PMID>25845704</PMID>
  </reference>
  <reference>
    <citation>Lubnow M, Philipp A, Dornia C, Schroll S, Bein T, Creutzenberg M, Diez C, Schmid C, Pfeifer M, Riegger G, M端ller T, Lehle K. D-dimers as an early marker for oxygenator exchange in extracorporeal membrane oxygenation. J Crit Care. 2014 Jun;29(3):473.e1-5. doi: 10.1016/j.jcrc.2013.12.008. Epub 2013 Dec 30.</citation>
    <PMID>24508200</PMID>
  </reference>
  <reference>
    <citation>Lehle K, Philipp A, Gleich O, Holzamer A, M端ller T, Bein T, Schmid C. Efficiency in extracorporeal membrane oxygenation-cellular deposits on polymethylpentene membranes increase resistance to blood flow and reduce gas exchange capacity. ASAIO J. 2008 Nov-Dec;54(6):612-7. doi: 10.1097/MAT.0b013e318186a807.</citation>
    <PMID>19033775</PMID>
  </reference>
  <reference>
    <citation>Sidebotham D, Allen SJ, McGeorge A, Ibbott N, Willcox T. Venovenous extracorporeal membrane oxygenation in adults: practical aspects of circuits, cannulae, and procedures. J Cardiothorac Vasc Anesth. 2012 Oct;26(5):893-909. doi: 10.1053/j.jvca.2012.02.001. Epub 2012 Apr 13. Review.</citation>
    <PMID>22503344</PMID>
  </reference>
  <reference>
    <citation>Lubnow M, Philipp A, Foltan M, Bull Enger T, Lunz D, Bein T, Haneya A, Schmid C, Riegger G, M端ller T, Lehle K. Technical complications during veno-venous extracorporeal membrane oxygenation and their relevance predicting a system-exchange--retrospective analysis of 265 cases. PLoS One. 2014 Dec 2;9(12):e112316. doi: 10.1371/journal.pone.0112316. eCollection 2014.</citation>
    <PMID>25464516</PMID>
  </reference>
  <reference>
    <citation>Panigada M, E Iapichino G, Brioni M, Panarello G, Protti A, Grasselli G, Occhipinti G, Novembrino C, Consonni D, Arcadipane A, Gattinoni L, Pesenti A. Thromboelastography-based anticoagulation management during extracorporeal membrane oxygenation: a safety and feasibility pilot study. Ann Intensive Care. 2018 Jan 16;8(1):7. doi: 10.1186/s13613-017-0352-8.</citation>
    <PMID>29340875</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Damian Ratano</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Extracorporeal membrane oxygenation</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

